SANDOZ has announced that its two new biosimiliar brands of denosumab, which is used to treat osteoporosis, are now listed on the Pharmaceutical Benefits Scheme (PBS).
More than 600,000 patients will now pay less to access Jubbonti 60mg/1ml solution for a prefilled syringe and Wyost 120mg/1.7ml solution for injection, which are the first new biosimiliar brands of denosumab available for public funding.
The PBS listing also creates new opportunities for community pharmacies, who can now administer denosumab injections in-pharmacy.
"The PBS listing of Jubbonti and Wyost marks a pivotal moment for healthcare sustainability in Australia," said Sandoz ANZ Head of Marketing, Natalie Armstrong.
The above article was sent to subscribers in Pharmacy Daily's issue from 01 Aug 25
To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 01 Aug 25
